We wish to inform you that the Company has entered into a Business transfer
agreement with Solara Active Pharma Sciences Limited to acquire the EU-GMP API
facility at Mahad (Mahad facility). The total consideration for the unit would be INR 46.4 crores on an Enterprise Valuation basis.
The acquired Mahad facility compliments our current manufacturing at Vizag
(USFDA approved) and Tarapur (Intermediates).
This is for your kind information.
Sequent Scientific: Acquisition Of European FDA Approval API Facility At Mahad From
Solara Active Pharma Sciences Limited (Solara)
September 22, 2018